SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    White B. Pathogenesis: immune aspects. In: ClementsPJ, FurstED, editors. Systemic sclerosis. Baltimore: Williams and Wilkins; 1996. p. 22950.
  • 2
    Galperin C, Gershwin ME. Systemic sclerosis (scleroderma). In: RoseNE, MackayIR, editors. The autoimmune diseases. 3rd ed. San Diego: Academic Press; 1998. p. 31742.
  • 3
    Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 14573.
  • 4
    Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 22757.
  • 5
    Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997; 151: 17518.
  • 6
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 32832.
  • 7
    Atamas SP, Yurovsky VV, Wigley FM, Goter Robinson CG, Henry P, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999; 42: 116878.
  • 8
    Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28: 261929.
  • 9
    Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, et al. Sclerodermatous chronic graft-versus-host-disease: analysis of seven cases. J Am Acad Dermatol 1992; 26: 4955.
  • 10
    De Wit D, van Mechelen M, Zanin C, Doutrelepont JM, Velu T, Gerard C, et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150: 3616.
  • 11
    Sakurai J, Ohata J, Saito K, Miyajima H, Hirano T, Kohsaka T, et al. Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft-versus-host disease by an enhanced expansion of regulatory CD8+ T cells. J Immunol 2000; 164: 6649.
  • 12
    Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998; 338: 118691.
  • 13
    Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, et al. Microchimerism and HLA-compatible relationship of pregnancy in scleroderma. Lancet 1998; 351: 55962.
  • 14
    Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999; 93: 20337.
  • 15
    Rooney DE, Crepulkowski BH. Human cytogenetics. Oxford: Oxford University Press; 1992.
  • 16
    Santamaria P, Lindstrom AL, Boyce-Jacino MT, Myster SH, Barbosa JJ, Faras AJ, et al. HLA class I sequence-based typing. Hum Immunol 1993; 37: 3950.